Tetraspanin CD81 promotes leukemia stem cell function and represents a new therapeutic vulnerability in acute myeloid leukemia

Despite important progress over the last decade, acute myeloid leukemia (AML) is still associated with poor clinical outcome. Novel potent therapies ideally effective against AML stem cells (LSC), a major driver of leukemia initiation and progression, are urgently needed. In particular, targeting common AML-associated antigens at the stem and progenitor cell level represents an attractive therapeutic strategy to achieve deep long-term remissions and is currently the subject of intensive research efforts. In this study, we identified the tetraspanin CD81, a cell surface antigen frequently expressed on AML cells including LSC, as a new determinant of relapse and poor prognosis. CD81 expression was higher in AML cells compared to normal bone marrow cells, and more markedly expressed at relapse. We further showed that modulation of CD81 expression using gain- and loss-of-function approaches affected leukemia aggressiveness, tumor burden, LSC-homing and - xenoengraftment as well as mouse survival. Finally, anti-hCD81 monoclonal antibody-treatment combined with standard chemotherapy in mice with pre-established AML not only reduced leukemia burden but also prolonged relapse-free and overall survival. Collectively, these results identified a new efficacious and safe pharmacological strategy for targeting LSC, opening up novel therapeutic avenues to improve AML outcome. Key pointsO_LICD81 expression in AML including LSC is a new determinant of aggressive disease and poor prognosis. C_LIO_LIAnti-hCD81 monoclonal antibody-treatment of AML xenografts reduced leukemia burden and improved survival rates. C_LI